Core Insights - Channel Therapeutics Corporation has achieved significant results in pre-clinical trials for its nerve block formulations, demonstrating improved efficacy and duration compared to the current standard of care, bupivacaine [1][4][5] Company Developments - The company conducted thermal hyperalgesia and mechanical allodynia tests in rodents, showing that three of its four formulations outperformed bupivacaine in efficacy and duration [3][4][5] - The formulations exhibited a depot effect lasting over four days, which is a notable improvement over bupivacaine [3][4] - The NaV1.7 inhibitors are believed to be a promising target for pain treatment, potentially reducing reliance on opioids post-surgery [6][7] Market Opportunity - The global post-operative pain market was valued at $2.6 billion in 2023, with Exparel generating approximately $538 million in revenue, indicating a substantial market for Channel's products [7] - The results from the trials suggest a potential to decrease post-surgical opioid usage, addressing a significant market need [7] Future Prospects - Results for the company's eye drop formulations targeting various types of eye pain are expected in late January 2025, indicating ongoing development in pain management solutions [8]
Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model